Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Slides:

Advertisements

Similar presentations

How to manage suspected cancer

Advertisements

Fig. 1. Flow diagram of study participants and outcomes.

From: An open day in the metric space

Fig. 3. Plot of overall survival by adjuvant therapy for patient subgroups. (A) Patients with M0 disease (n = 411). (B) Patients receiving 36 Gy craniospinal.

Fig. 1 Flow chart of the COBRA-light trial and its extension study

From: Global Banking: Recent Developments and Insights from Research*

Figure 2. Quality of life (QOL) scores for functional scale items

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Scree plot for the exploratory factor analysis (EFA) of the Death Depression Scale (DDS). From: Development and psychometric evaluation of a.

Figure 2. CONSORT flow diagram.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

Test characteristics of MRI-detected inflammation for the development of arthritis in CSA patients (A) and RA in UA patients (B) during 1-year follow-up.

Figure 1. Mean recalled time (days) since the start of the last quit attempt by use of stop-smoking medications (SSM) and Heaviness of Smoking Index (HSI)

Error bars represent the mean (s.e.).

pSS: primary SS; Scl: scleroderma.

Figure 3. Examples of tweets classified as ridicule.

Figure 1. Selection of papers.

Figure 1. Conceptual model of well-being related to involvement in theatre. From: Theatre Involvement and Well-Being, Age Differences, and Lessons From.

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1. Orthodontic set-up and location of LLLT or placebo-laser

Fig. 1 Flow of ascertainment of cases with incident childhood IgA vasculitis reported by four sources From: Incidence of IgA vasculitis in children estimated.

Figure 1 (A) Chest computed tomography scans of the patient

Figure 2. (A) Sézary syndrome patient before treatment

Figure 2. Kaplan–Meier survival analysis in patients

From: Where do we go from here

Figure 1. Overall survival of patients receiving alternative medicine (solid lines) vs conventional cancer treatment (dashed lines). Overall survival of.

Figure 2. A consort diagram showing the flowchart of the trial

Figure 1. Relationship between Log Transfers and Age of Eldest HH Member(a) Bandwidth 0.05(b) Bandwidth 0.1(c) Bandwidth 0.5 From: The Effect of a Transfer.

Fig. 1 Selection of patients

Figure 1 Study flowchart.

Fig. 1 Flow diagram of patient selection and study design.

Figure 1 Flow of data processing

Figure 1. Examples of e-cigarette discussions in social media

From: Estimating the Location of World Wheat Price Discovery

Figure 1: Time points at which sperm samples were analysed for aneuploidy frequencies in controls and cancer patients From: Sperm aneuploidy frequencies.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. Percentage of trainees is represented on the y-axis for each competency/knowledge item represented in the x-axis. Only Poor/Fair (P/F) ratings.

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 6. RRs for clinical cure rates stratified by different diseases

Fig. 2. Diagram of the annual induction and release cycle of summer dormancy in a herbaceous perennial species and the associated variations in phytohormone.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Figure 5. Tungiasis: a 21-year-old woman returned from Peru with painful nodules on her toes. From: Illness in Travelers Returned From Brazil: The GeoSentinel.

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

Volume 54, Issue 2, Pages (August 2008)

توزیع جغرافیایی مرگ به دلیل بدخیمی در کشور Age-standardized incidence rate of all cancers per 100 000 in female in Iran 2005–2006.

Overview of the QTWiST method

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

The 10-year cumulative incidence of CRC death or death due to other causes in patients treated with adjuvant chemotherapy after surgery for stages II–III.

Mean difference between treatment groups in the change from baseline for all PRO scores at months 1, 2 and 3. *Evaluable patients. Mean difference between.

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial)

Kaplan-Maier survival curves of 10-year DFS (A and B) and OS (C and D) according to PS 0 and PS≥1 in patients treated with adjuvant chemotherapy after.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Figure 1. CONSORT flow diagram

Mean change from baseline for perceived cognitive impairments (A), cognitive functioning (B), usual level of fatigue (C) and fatigue interference (D) at.

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Figure 2. Kaplan–Meier curves derived from data generated under study-specific assumptions. (A) Kaplan–Meier curves ... Figure 2. Kaplan–Meier curves derived.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Figure 1. The proportion of CSBM responders over the 2-week treatment period (A), the proportion of SBM responders by ... Figure 1. The proportion of CSBM.

Figure 1. Longitudinal measures of HIV persistence and immunologic phenotype/function during anti-PD-1 therapy are ... Figure 1. Longitudinal measures.

The figure shows the fraction of ...

Figure 1. A summary of phase 3 trials for previously untreated advanced/metastatic NSCLC. AEs, adverse events; Beva, ... Figure 1. A summary of phase 3.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Presentation transcript:

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4):911-918. doi:10.1093/annonc/mdr329 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 2. Dose modification diagram in all enrolled patients (N = 82). From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4):911-918. doi:10.1093/annonc/mdr329 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 3. The change in dose intensity during capecitabine chemotherapy (mean and standard error, mg/m<sup>2</sup>/day). From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4):911-918. doi:10.1093/annonc/mdr329 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 4. Kaplan–Meier curves of disease-free survival (A), recurrence-free survival (B), and overall survival (C). From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4):911-918. doi:10.1093/annonc/mdr329 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 5. The mean scores (circle) and standard deviation (bar) of scales and items of the QLQ-C30 just before the adjuvant chemotherapy (N = 57). One global scale (QL) and five functional scales, including physical functioning (PF), role functioning (RF), emotional functioning (EF), cognitive functioning (CF), and social functioning (SF), are shown on the left side; a higher score reflects a better level of functioning. Nine symptom scales, including fatigue (FA), nausea and vomiting (NV), pain (PA), dyspnea (DY), sleep disturbance (SL), appetite loss (AP), constipation (CO), diarrhea (DI), and financial difficulties (FI), are shown on the right side; a higher score represents a worse level of symptom. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4):911-918. doi:10.1093/annonc/mdr329 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com

Figure 6. (A) The changes of quality of life (QoL) scores in five functional and one global scales and (B) the changes of QoL scores in nine symptom scales. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer Ann Oncol. 2010;23(4):911-918. doi:10.1093/annonc/mdr329 Ann Oncol | © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com